Amytrx Therapeutics, a US-based biopharmaceutical company specialising in the development of novel therapies for dermatology and inflammation, announced on Tuesday that it has added Dr Michael Howell and Dr Satish Joshi as its new directors.
Dr Howell has over 20 years of experience in allergy, autoimmunity, dermatology, inflammatory and oncology diseases. He has played an important role in various clinical trials and has published extensively on topics regarding dermatological and immunological conditions.
Dr Joshi has more than 25 years of experience in the peptide API business. He has been at the forefront of peptide product development throughout his career.
Dr Matthew A. Gonda, Amytrx Therapeutics CEO, said: "Amytrx Therapeutics is excited to welcome Dr. Howell and Dr. Joshi to our board of directors. Their exceptional scientific and business backgrounds align perfectly with our mission to bring transformative treatments to patients in need. Their contributions will be invaluable as we continue to advance our lead candidate, AMTX-100, and work towards its successful commercialisation."
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
Delta-Fly Pharma initiates Phase III trial for lung cancer drug DFP-14323
Q32 Bio added to Russell 3000 Index
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Triveni Bio appoints new chief medical officer, announces key program updates
UCB presents bimekizumab two-year data for axial spondyloarthritis and psoriatic arthritis
GIE Medical commences patient enrolment for Chronic Benign Stricture - Bowel (PATENT-B) study
Sen-Jam Pharmaceutical signs third strategic partnership with KVK-Tech
IASO Biotechnology's BCMA CAR-T (Equecabtagene Autoleucel) IND application receives FDA approval